Dental Bone Graft Substitutes and Barrier Membrane Market Size, Share, Growth by 2030

The market for Dental Bone Graft Substitutes and Barrier Membranes was valued at approximately US$ 722.04 million in 2022 and is projected to grow to around US$ 1,379.92 million by 2030, reflecting a compound annual growth rate (CAGR) of 8.4% from 2023 to 2030.

This market expansion is primarily driven by the rising prevalence of periodontal diseases and oral cancers, alongside increased activities aimed at market development within the dental bone graft substitute and barrier membrane sectors. Nevertheless, the high costs associated with these products and delays in dental appointments pose challenges to market growth.

Strategic initiatives such as product introductions, mergers and acquisitions, and market expansions are pivotal in propelling the growth of the dental bone graft substitute and barrier membrane market. For instance, in April 2023, ZimVie launched the RegenerOss CC Allograft Particulate and RegenerOss Bone Graft Plug, enhancing its biomaterials portfolio designed for filling extraction sockets and addressing periodontal defects. These products are now available in North America. In May 2023, Straumann completed the acquisition of GalvoSurge Dental AG, a Swiss company that specializes in solutions for implant care and maintenance, particularly for treating peri-implantitis.

In October 2022, Geistlich, a company focused on bone, cartilage, and tissue regeneration, acquired Lynch Biologics in the United States. This acquisition allowed Geistlich Pharma to enhance its offerings by incorporating Lynch Biologics, LLC's prominent GEM 21S product, which is based on a growth factor that promotes bone formation and accelerates wound healing. Both companies are committed to advancing regenerative technologies in the field of dentistry. Additionally, in December 2022, Neoss Group, known for designing and manufacturing dental implant treatment products, inaugurated a new sales office in the Nordic region to better support dental professionals and their patients starting December 1, 2022. Furthermore, in January 2021, Dentsply Sirona acquired Datum Dental, a leader in innovative OSSIX regenerative solutions, which allowed Dentsply Sirona to integrate Datum Dental's robust OSSIX biomaterial portfolio and gain access to its patented GLYMATRIX technology. This technology emulates the natural collagen cycle in the body, known as glycation, and serves as the foundation for OSSIX products used in guided bone and tissue regeneration.

The dental bone graft substitute and barrier membrane market is categorized by product type into dental bone graft substitutes and dental barrier membranes. In 2022, the dental bone graft substitute segment commanded a larger share of the market; however, the dental barrier membrane segment is expected to experience a higher CAGR of 9.0% throughout the forecast period. The dental bone graft substitute category is further divided into allografts, autografts, xenografts, synthetic bone grafts, alloplasts, and demineralized bone matrix (DBM), among others. The dental barrier membrane segment is classified into resorbable and non-resorbable membranes.

In the field of dentistry, barrier membranes play a crucial role in enhancing the outcomes of periodontal tissue regeneration and bone augmentation related to implant procedures. As bone defects heal, there is a competitive dynamic between soft tissue and bone-forming cells vying for access to the surgical site, with soft tissue cells typically migrating more rapidly than their bone-forming counterparts.

Consequently, the primary objective of barrier membranes is to facilitate selective cell repopulation and regulate the growth of various tissues during the healing phase. Dental barrier membranes are engineered to foster tissue regeneration and can be categorized based on the biodegradability of their base materials. Membranes utilized in guided bone regeneration (GBR) and transplantation are primarily classified into two types: non-resorbable and resorbable. These membranes differ in their biomaterial composition and physical characteristics, each presenting unique advantages and disadvantages suited to different clinical scenarios.

Key primary and secondary sources utilized in the preparation of the report on the dental bone graft substitute and barrier membrane market include the United States Food and Drug Administration (USFDA), the Global Cancer Observatory (GCO), the Centers for Disease Control and Prevention (CDC), and the South African Dental Association (SADA).